Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome

Clinica Chimica Acta

Volumn 431, Issue , 2014, Pages 174-178

  Mondejar, R ^a   Gonzalez Rodriguez C ^a   Toyos Saenz de Miera F J ^a   Melguizo Madrid, E ^a   Zohoury, N ^b   Mahler, M ^b   Romero Losquino I ^a   Fabiani, F ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b INOVA DIAGNOSTICS INC   (United States)

Author keywords

Antiphospholipid syndrome; Autoantibodies; Beta 2 glycoprotein I Domain 1; Thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN;

ADULT; ANTIPHOSPHOLIPID SCORE; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CHEMILUMINESCENT IMMUNOASSAY; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MALE; MORBIDITY; PREVALENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; THROMBOSIS; VALIDATION PROCESS; BLOOD; IMMUNOLOGY; LUMINESCENCE; MIDDLE AGED; PATHOPHYSIOLOGY; REPRODUCIBILITY;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CARDIOLIPINS; FEMALE; HUMANS; LUMINESCENCE; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS;

EID: 84896725362     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.01.047     Document Type: Article

References (30)

1. Meroni P.L., Borghi M.O., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011, 7:330-339.
2. Meroni P.L., Shoenfeld Y. Predictive, protective, orphan autoantibodies: the example of anti-phospholipid antibodies. Autoimmun Rev 2008, 7:585-587.
3. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
4. McNeil H.P., Simpson R.J., Chesterman C.N., Krilis S.A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990, 87:4120-4124.
5. Iverson G.M., Reddel S., Victoria E.J., et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002, 169:7097-7103.
6. de Laat B., van Berkel M., Urbanus R.T., et al. Immune responses against domain I of β(2)-glycoprotein I are driven by conformational changes: domain I of β(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum 2011, 63:3960-3968.
7. Iverson G.M., Victoria E.J., Marquis D.M. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A 1998, 95:15542-15546.
8. Mahler M., Norman G.L., Meroni P.L., Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 2012, 12:313-317.
9. Otomo K., Atsumi T., Amengual O., et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 2012, 64:504-512.
10. Sciascia S., Bertolaccini M.L., Roccatello D., Khamashta M.A. Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis 2013, 72:142-143.
11. Mahler M., Radice A., Yang W., et al. Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies. Clin Chim Acta 2012, 413:719-726.
12. Pengo V., Tripodi A., Reber G., et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009, 7:1737-1740.
13. Fijorek K., Fijorek D., Wisniowska B., Polak S. BDTcomparator: a program for comparing binary classifiers. Bioinformatics 2011, 27:3439-3440.
14. Nofuentes J.A., Del Castillo J.D. Comparison of the likelihood ratios of two binary diagnostic tests in paired designs. Stat Med 2007, 26:4179-4201.
15. Noubouossie D., Valsamis J., Corazza F., Rozen L., Debaugnies F., Demulder A. An automated chemiluminescence immunoassay may detect mostly relevant IgG anticardiolipin antibodies according to revised Sydney criteria. Acta Clin Belg 2012, 67:184-189.
16. Van Hoecke F., Persijn L., Decavele A.S., Devreese K. Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Int J Lab Hematol 2012, 34:630-640.
17. Chung Y., Kim J.E., Lim H.S., Kim H.K. Clinical performance of anticardiolipin and antibeta2 glycoprotein I antibodies using a new automated chemiluminescent assay: superior thrombotic prediction of combined results measured by two different methods. Blood Coagul Fibrinolysis 2014, 25:10-15.
18. Andreoli L., Nalli C., Motta M., et al. Anti-beta(2)-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile?. Ann Rheum Dis 2011, 70:380-383.
19. de Laat B., de Groot P.G. Autoantibodies directed against domain I of beta2-glycoprotein I. Curr Rheumatol Rep 2011, 13:70-76.
20. Iverson G.M., Matsuura E., Victoria E.J., Cockerill K.A., Linnik M.D. The orientation of beta2GPI on the plate is important for the binding of anti-beta2GPI autoantibodies by ELISA. J Autoimmun 2002, 18:289-297.
21. de Laat B., Pengo V., Pabinger I., et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009, 7:1767-1773.
22. Zohoury N., Khamashta M., Atsumi T., et al. Autoantibodies targeting domain 1 of beta 2 glycoprotein I as promising marker In the diagnosis and risk stratification of the antiphospholipid syndrome. Arthritis Rheum 2013, 65:10.
23. Pengo V., Banzato A., Bison E., Bracco A., Denas G., Ruffatti A. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts?. Semin Thromb Hemost 2012, 38:322-327.
24. Pengo V., Ruffatti A., Legnani C., et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011, 118:4714-4718.
25. Ruffatti A., Tonello M., Visentin M.S., et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford) 2011, 50:1684-1689.
26. Pengo V., Ruffatti A., Del R.T., et al. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J Thromb Haemost 2013, 11:1527-1531.
27. Guidelines for immunologic laboratory testing in the rheumatic diseases: an introduction. Arthritis Rheum 2002, 47:429-433.
28. Mehrani T., Petri M. Association of IgA Anti-beta2 glycoprotein I with clinical and laboratory manifestations of systemic lupus erythematosus. J Rheumatol 2011, 38:64-68.
29. Akhter E., Shums Z., Norman G.L., Binder W., Fang H., Petri M. Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. J Rheumatol 2013, 40:282-286.
30. Erkan D., Lockshin M.D. APS ACTION-AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. Lupus 2012, 21:695-698.